华兰生物：利妥昔单抗注射液的上市申请正在CDE审评过程中

Core Viewpoint - The company is advancing its drug development pipeline with promising clinical results for its diabetes treatment and is progressing towards regulatory approval for another product [1] Group 1: Drug Development - The recombinant Exendin-4-FC fusion protein injection is a long-acting GLP-1 receptor agonist for type 2 diabetes treatment, having successfully completed Phase I/II clinical trials with comprehensive efficacy and safety data [1] - The company is preparing to initiate Phase III clinical trials for the Exendin-4-FC fusion protein injection [1] Group 2: Regulatory Progress - The company's subsidiary, Hualan Gene Engineering Co., Ltd., submitted a marketing application for rituximab injection on November 22, 2024, which is currently under review by the CDE [1]